表纸
市场调查报告书

药物研发服务的全球市场:各流程、类型、药物类型、治疗、企业- 至2025年的预测

Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025

出版商 MarketsandMarkets 商品编码 923896
出版日期 内容资讯 英文 233 Pages
订单完成后即时交付
价格
药物研发服务的全球市场:各流程、类型、药物类型、治疗、企业- 至2025年的预测 Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
出版日期: 2020年09月03日内容资讯: 英文 233 Pages
简介

全球药物研发服务市场预测将从2020年的107亿美元以年复合成长率12.1%扩大,到2025年达到191亿美元的规模。该市场的成长,是由于对医药品,生物医药品产业的研究开发费用的扩大,分析实验和临床实验服务的外包需求扩大,罕见疾病,孤儿药研究的配合措施,对药物研发的著重等要素。还有发展中国家预期对加入此市场的主要企业来说提供广泛的成长机会。

本报告提供全球药物研发服务市场相关调查,各市场区隔趋势,至2025年的成长预测,各地区趋势,及加入此市场的主要企业的简介等相关资讯。

第1章 简介

第2章 调查方法

第3章 摘要整理

第4章 高级见解

第5章 市场概要

  • 简介
  • 市场趋势
    • 促进要素
    • 阻碍要素
    • 机会
    • 趋势

第6章 药物研发服务市场:各流程

  • 简介
  • 标的选择
  • 标的验证
  • 先导化合物创制流程的识别
  • 先导药物最适化
  • 候补验证

第7章 药物研发服务市场:各类型

  • 简介
  • 医科学服务
  • 生物学服务
  • 药物代谢,药物动力学学

第8章 药物研发服务市场:各药物类型

  • 简介
  • 低分子药物
  • 生技药品

第9章 药物研发服务市场:各治疗领域

  • 简介
  • 肿瘤
  • 神经
  • 感染疾病,免疫系疾病
  • 消化系疾病
  • 心血管疾病
  • 其他治疗领域

第10章 药物研发服务市场:各类型企业

  • 简介
  • Tier 1
  • Tier 2
  • Tier 3

第11章 药物研发服务市场:各地区

  • 简介
  • 北美
  • 欧洲
  • 亚太地区
  • 其他各国

第12章 竞争环境

  • 概要
  • 市场占有率分析
  • 竞争模式
  • 竞争领导制图

第13章 企业简介

第14章 附录

目录
Product Code: PH 5682

"Increasing R&D spending and initiatives for rare disease and orphan drugs research are set to drive the drug discovery services market."

The drug discovery services market is projected to reach USD 21.4 billion by 2025 from USD 11.1 billion in 2020, at a CAGR of 14.0% during the forecast period. The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. However, the high cost of drug discovery and development and stringent regulations governing drug discovery and animal usage in testing may restrict the growth of this market to a certain extent.

"By process, the Hit-to-Lead process accounted for the fastest-growing segment of the drug discovery service market."

Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

"By type, the Medicinal Chemistry segment accounted for the largest share of the drug discovery service market."

Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

"Oncology segment expected to grow at the fastest growth rate during the forecast period."

Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market during forecast period.. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

"Asia Pacific: The fastest-growing region in the drug discovery services market."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their manufacturing and drug discovery R&D operations to the region. As a result, the Asia Pacific region has become a major destination for drug discovery and development. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.

"North America: The largest share of the drug discovery servics market."

North America, which includes the US and Canada, accounted for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Break-up of Primaries:

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.

The break-up of the primaries is as follows:

  • By Company- Tier 1- 40%, Tier 2- 30%, Tier 3- 30%
  • By Designation- Executives- 25%, CXOs- 20%, Managers - 55%
  • By Region- North America - 50%, Europe - 20%, APAC - 20%, RoW- 10%

The drug discovery services market is dominated by a few globally established players such as Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Domainex (UK), GenScript Biotech Corporation (China), Laboratory Corporation of America Holdings (US), WuXi AppTec (China), Pharmaceutical Product Development, LLC (US), Jubilant Biosys Ltd. (India), Eurofins Scientific SE (Luxembourg), Piramal Enterprises Ltd. (India), and Selvita S.A. (Poland).

Research Coverage:

The report segments the drug discovery services market based on region (North America, Asia Pacific, Europe, and RoW), process (target selection, target validation,hit-to-lead identification,lead optimization and candidate validation), type (medicinal chemistry, biology services, Drug Metabolism and Pharmacokinetics (DMPK)), and drug type (small molecules and biologics),Therapeutic Area ( Oncology, Neurology, infectious and Immune System Diseases, Diagestive System Disease, Cardiovascular Disease and others), Company type (Tier 1, tier 2, Tier3 pharmaceutical companies).The report also provides a comprehensive review of market drivers, challenges, and opportunities in the drug discovery services market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the ISH market and provides them information on key market drivers, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • FIGURE 4 BOTTOM-UP APPROACH
    • 2.2.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    • FIGURE 5 TOP-DOWN APPROACH
    • 2.2.3 GROWTH FORECAST
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020 VS. 2025 (USD MILLION)
    • FIGURE 8 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020 VS. 2025
    • FIGURE 9 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
    • FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY REGION

4 PREMIUM INSIGHTS

  • 4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
    • FIGURE 12 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE & COUNTRY (2020)
    • FIGURE 13 SMALL-MOLECULE DRUGS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2020
  • 4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
    • TABLE 1 DRUG DISCOVERY PROCESS OVERVIEW
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
    • FIGURE 16 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2001-2018 (USD BILLION)
      • 5.2.1.2 Increasing demand for outsourcing analytical testing and clinical trial services
    • FIGURE 17 ACTIVE PHARMACEUTICAL PIPELINE, JANUARY 2009-JANUARY 2019
      • 5.2.1.3 Initiatives for research on rare diseases and orphan drugs
    • TABLE 2 RESEARCH PROJECTS FUNDED BY THE IRDIRC
    • FIGURE 18 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010-2017)
      • 5.2.1.4 Focus on drug discovery
    • FIGURE 19 NUMBER OF REGISTERED STUDIES (2005-2017)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of drug discovery and development
    • TABLE 3 AVERAGE COST OF DRUGS APPROVED PER YEAR, 2004-2013
    • FIGURE 20 AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUG- INCLUDING THE COST OF FAILURES
      • 5.2.2.2 Stringent regulations governing drug discovery and animal usage
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth in the biologics market
      • 5.2.3.2 Patent expiries
      • 5.2.3.3 Emerging markets
    • 5.2.4 TRENDS
      • 5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery
  • 5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET

6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

  • 6.1 INTRODUCTION
    • TABLE 4 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
  • 6.2 TARGET SELECTION
    • 6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
    • TABLE 6 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 7 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2020-2025 (USD MILLION)
  • 6.3 TARGET VALIDATION
    • 6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 8 ADVANTAGES AND DISADVANTAGES OF SIRNA
    • TABLE 9 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2020-2025 (USD MILLION)
  • 6.4 HIT-TO-LEAD IDENTIFICATION
    • 6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
    • TABLE 11 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 12 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2020-2025 (USD MILLION)
  • 6.5 LEAD OPTIMIZATION
    • 6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
    • TABLE 13 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 14 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2020-2025 (USD MILLION)
  • 6.6 CANDIDATE VALIDATION
    • 6.6.1 CANDIDATE VALIDATION SEGMENT TO GROW AT A HIGH CAGR DURING THE FORECAST PERIOD
    • TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2020-2025 (USD MILLION)

7 DRUG DISCOVERY SERVICES MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 17 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 18 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
  • 7.2 MEDICINAL CHEMISTRY SERVICES
    • 7.2.1 WIDE APPLICATIONS OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY ARE A MAJOR FACTOR DRIVING MARKET GROWTH
    • TABLE 19 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 20 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 7.3 BIOLOGY SERVICES
    • 7.3.1 RESTRICTIONS ON THE USAGE OF ANIMALS IN RESEARCH ACTIVITIES MAY LIMIT MARKET GROWTH
    • TABLE 21 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 22 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 7.4 DRUG METABOLISM & PHARMACOKINETICS
    • 7.4.1 DMPK STUDIES ARE EMPLOYED AT THE DISCOVERY, CANDIDATE SELECTION, INVESTIGATIONAL NEW DRUG, AND NEW DRUG APPLICATION STAGES
    • TABLE 23 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 24 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020-2025 (USD MILLION)

8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

  • 8.1 INTRODUCTION
    • TABLE 25 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 26 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
  • 8.2 SMALL-MOLECULE DRUGS
    • 8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET DURING THE FORECAST PERIOD
    • TABLE 27 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 28 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 2020-2025 (USD MILLION)
  • 8.3 BIOLOGIC DRUGS
    • 8.3.1 HIGH SET-UP COSTS OF THE INSTRUMENTS REQUIRED FOR BIOLOGIC DRUG MANUFACTURING MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT
    • TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2020-2025 (USD MILLION)

9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

  • 9.1 INTRODUCTION
    • TABLE 31 GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA (AS OF OCTOBER 2019)
    • FIGURE 21 R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019
    • TABLE 32 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 33 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
  • 9.2 ONCOLOGY
    • 9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
    • FIGURE 22 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY, BY REGION (AS OF DECEMBER 2019)
    • TABLE 34 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 35 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 2020-2025 (USD MILLION)
  • 9.3 NEUROLOGY
    • 9.3.1 INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
    • TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 37 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 2020-2025 (USD MILLION)
  • 9.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES
    • 9.4.1 EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    • TABLE 38 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 39 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 2020-2025 (USD MILLION)
  • 9.5 DIGESTIVE SYSTEM DISEASES
    • 9.5.1 AS THERE IS A HUGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES, PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS
    • TABLE 40 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 41 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2020-2025 (USD MILLION)
  • 9.6 CARDIOVASCULAR DISEASES
    • 9.6.1 HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
    • TABLE 42 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2025 (USD MILLION)
  • 9.7 OTHER THERAPEUTIC AREAS
    • TABLE 44 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 45 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020-2025 (USD MILLION)

10 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE

  • 10.1 INTRODUCTION
    • TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2016-2019 (USD MILLION)
    • TABLE 47 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2020-2025 (USD MILLION)
  • 10.2 TIER 1 PHARMACEUTICAL COMPANIES
    • TABLE 48 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 49 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 2020-2025 (USD MILLION)
  • 10.3 TIER 2 PHARMACEUTICAL COMPANIES
    • TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 51 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 2020-2025 (USD MILLION)
  • 10.4 TIER 3 PHARMACEUTICAL COMPANIES
    • TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 2020-2025 (USD MILLION)

11 DRUG DISCOVERY SERVICES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 54 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 55 DRUG DISCOVERY SERVICES MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 23 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
    • TABLE 56 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 57 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 58 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 59 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 60 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 61 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 62 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 63 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 64 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 65 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • TABLE 66 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2016-2019 (USD MILLION)
    • TABLE 67 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2020-2025 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
    • FIGURE 25 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
    • TABLE 68 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
    • TABLE 69 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 70 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 71 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 72 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 73 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 74 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 75 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 76 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
    • TABLE 77 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
    • TABLE 78 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017
    • TABLE 79 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 80 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 81 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 82 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 83 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 84 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 85 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 86 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 87 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 89 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 90 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 91 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 92 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 93 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 95 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 96 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • TABLE 97 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2016-2019 (USD MILLION)
    • TABLE 98 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2020-2025 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
    • TABLE 99 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 100 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 101 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 102 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 103 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 104 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 105 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 106 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Investment by pharmaceutical sponsors in the UK for drug discovery services to support market growth
    • FIGURE 26 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017
    • TABLE 107 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 108 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 109 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 110 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 111 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 112 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 113 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 114 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 High number of oncology clinical trials in France to drive market growth
    • TABLE 115 NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017
    • TABLE 116 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 117 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 118 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 119 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 120 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 121 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 122 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 123 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
    • TABLE 124 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
    • TABLE 125 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 126 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 127 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 128 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 129 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 130 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 131 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 132 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
    • FIGURE 27 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011-2017
    • TABLE 133 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 134 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 135 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 136 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 137 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 138 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 139 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 140 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 141 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 142 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 143 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 144 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 145 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 146 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 147 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 148 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • TABLE 149 TOTAL NUMBER OF CLINICAL TRIALS IN THE APAC, BY THERAPEUTIC AREA, 2017
    • FIGURE 28 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
    • TABLE 150 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 151 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 152 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 153 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 154 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 155 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 156 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 157 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 158 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 159 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Low cost of clinical trials and large pharmaceutical R&D footprint in China to drive market growth
    • TABLE 160 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 161 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 162 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 163 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 164 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 165 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 166 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 167 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.4.2 INDIA
      • 11.4.2.1 Low-cost services and availability of skilled workforce to support market growth in India
    • TABLE 168 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 169 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 170 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 171 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 172 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 173 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 174 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 175 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.4.3 JAPAN
      • 11.4.3.1 Government initiatives for drug innovation to support market growth in Japan
    • TABLE 176 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 177 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 178 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 179 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 180 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 181 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 182 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 183 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 184 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 185 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 186 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 187 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 188 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 189 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 190 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 191 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 192 ROW: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 193 ROW: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 194 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 195 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020-2025 (USD MILLION)
    • TABLE 196 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 197 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 198 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 199 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 200 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 201 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • TABLE 202 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2016-2019 (USD MILLION)
    • TABLE 203 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 2020-2025 (USD MILLION)
    • 11.5.1 LATIN AMERICA
      • 11.5.1.1 Increasing investment and R&D to drive market growth in Latin America
    • TABLE 204 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2016-2019 (USD MILLION)
    • TABLE 205 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY PROCESS 2020-2025 (USD MILLION)
    • TABLE 206 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 207 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 208 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 209 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 210 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 211 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)
    • 11.5.2 MIDDLE EAST & AFRICA (MEA)
      • 11.5.2.1 Growing pharmaceutical industry to drive market growth in the Middle East and Africa
    • TABLE 212 MEA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 213 MEA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 214 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2016-2019 (USD MILLION)
    • TABLE 215 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 216 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2016-2019 (USD MILLION)
    • TABLE 217 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020-2025 (USD MILLION)
    • TABLE 218 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2016-2019 (USD MILLION)
    • TABLE 219 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2020-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 MARKET SHARE ANALYSIS
    • FIGURE 29 DRUG DISCOVERY SERVICES MARKET SHARE (2019)
  • 12.3 COMPETITIVE SCENARIO
    • 12.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
    • TABLE 220 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2018-2020)
    • 12.3.2 SERVICE LAUNCHES
    • TABLE 221 SERVICE LAUNCHES (2018-2020)
    • 12.3.3 MERGERS & ACQUISITIONS
    • TABLE 222 MERGERS & ACQUISITIONS (2018-2020)
    • 12.3.4 EXPANSIONS
    • TABLE 223 EXPANSIONS (2018-2019)
  • 12.4 COMPETITIVE EVALUATION MATRIX
    • 12.4.1 STARS
    • 12.4.2 PERVASIVE
    • 12.4.3 DYNAMIC LEADERS
    • 12.4.4 EMERGING COMPANIES
    • FIGURE 30 GLOBAL DRUG DISCOVERY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)

13 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)**

  • 13.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • FIGURE 31 LABCORP: COMPANY SNAPSHOT (2019)
  • 13.2 EUROFINS SCIENTIFIC SE
    • FIGURE 32 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2019)
  • 13.3 CHARLES RIVER LABORATORIES INTERNATIONAL
    • FIGURE 33 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2019)
  • 13.4 EVOTEC SE
    • FIGURE 34 EVOTEC SE: COMPANY SNAPSHOT (2019)
  • 13.5 THERMO FISHER SCIENTIFIC
    • FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
  • 13.6 SYNGENE INTERNATIONAL LIMITED
    • FIGURE 36 SYNGENE: COMPANY SNAPSHOT (2019)
  • 13.7 JUBILANT LIFESCIENCES
    • FIGURE 37 JUBILANT LIFESCIENCES: COMPANY SNAPSHOT (2018)
  • 13.8 GENSCRIPT BIOTECH CORPORATION
    • FIGURE 38 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2019)
  • 13.9 PIRAMAL ENTERPRISES LIMITED
    • FIGURE 39 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2019)
  • 13.10 WUXI APPTEC
    • FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2019)
  • 13.11 SELVITA (FORMERLY SELVITA CRO S.A.)
    • FIGURE 41 SELVITA: COMPANY SNAPSHOT (2019)
  • 13.12 FRONTAGE HOLDINGS
    • FIGURE 42 FRONTAGE HOLDINGS: COMPANY SNAPSHOT (2019)
  • 13.13 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
    • FIGURE 43 PHARMACEUTICAL PRODUCT DEVELOPMENT : COMPANY SNAPSHOT (2019)
  • 13.14 SHANGHAI MEDICILON, INC.
  • 13.15 ALBANY MOLECULAR RESEARCH, INC.
  • 13.16 AURIGENE DISCOVERY TECHNOLOGIES (A SUBSIDIARY OF DR. REDDY'S LABORATORIES)
  • 13.17 DOMAINEX LTD.
  • 13.18 CHEMPARTNER CO., LTD.
  • 13.19 TCG LIFESCIENCES PVT. LIMITED
  • 13.20 VIVA BIOTECH (SHANGHAI) LTD.

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies

14 ADJACENT RELATED MARKETS

  • 14.1 INTRODUCTION
  • 14.2 LIMITATIONS
  • 14.3 CONTRACT RESEARCH ORGANIZATION (CRO) SERVICE MARKET
    • 14.3.1 MARKET DEFINITION
    • 14.3.2 MARKET OVERVIEW
    • 14.3.3 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION
    • TABLE 224 CRO SERVICES MARKET, BY REGION, 2017-2025 (USD MILLION)
      • 14.3.3.1 North America
    • TABLE 225 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 14.3.3.2 Europe
    • TABLE 226 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 14.3.3.3 Asia Pacific
    • TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 14.4 CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) MARKET
    • 14.4.1 MARKET DEFINITION
    • 14.4.2 MARKET OVERVIEW
    • 14.4.3 CTMS MARKET, BY REGION
    • TABLE 228 CTMS MARKET, BY REGION, 2015-2022 (USD MILLION)
      • 14.4.3.1 North America
    • TABLE 229 NORTH AMERICA: CTMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • 14.4.3.2 Europe
    • TABLE 230 EUROPE: CTMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • 14.4.3.3 Asia Pacific
    • TABLE 231 ASIA PACIFIC: CTMS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • 14.5 DRUG DISCOVERY INFORMATICS MARKET
    • 14.5.1 MARKET DEFINITION
    • 14.5.2 MARKET OVERVIEW
    • 14.5.3 DRUG DISCOVERY INFORMATICS MARKET, BY REGION
    • TABLE 232 DRUG DISCOVERY INFORMATICS MARKET, BY REGION, 2017-2025 (USD MILLION)
      • 14.5.3.1 North America
    • TABLE 233 NORTH AMERICA: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
      • 14.5.3.2 Europe
    • TABLE 234 EUROPE: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 2017-2025
      • 14.5.3.3 Asia Pacific
    • TABLE 235 APAC: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 2017-2025 (USD MILLION)

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 AVAILABLE CUSTOMIZATIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS